John Carr

FOR YEARS, PHARMACEUTICAL companies abided by stringent guidelines when marketing products directly to consumers—even describing the condition a drug was designed to treat was cost-prohibitive. However, in August of 1997, the Food and Drug Administration revised the rules. It wasn’t long before an evening of television was not complete without families frolicking free of nasal allergies, thirty-somethings rediscovering life after depression and Bob Dole telling the world how his marriage was reinvigorated. Good news for the pharmaceutical companies, but not for the promotional companies previously responsible for most of the industry’s advertising, right? Wrong. A decade later, the pharmaceutical industry continues to grow at an